Diakatou Evanthia, Alexandraki Krystallenia I, Tsolakis Apostolos V, Kontogeorgos George, Chatzellis Eleftherios, Leonti Anastasia, Kaltsas Gregory A
Department of Pathology, "G. Gennimatas" Athens General Hospital, Athens, Greece.
Department of Pathophysiology, University of Athens, Athens, Greece.
Clin Endocrinol (Oxf). 2015 Sep;83(3):420-8. doi: 10.1111/cen.12775. Epub 2015 Apr 24.
The expression of somatostatin (sstr1-5) and dopamine (DR) receptors in neuroendocrine neoplasms (NENs) facilitates diagnosis by tumour visualization with somatostatin receptor scintigraphy (SRS) and directs towards specific treatment with peptide receptor radionuclide therapy (PRRT) with radiolabelled somatostatin analogues.
To investigate the co-expression of sstrs, D2R in relation to pre-operative SRSs in NENs.
Prospective two-centre study.
We analysed pre-operative SRS of 60 patients [44 with gastrointestinal (GI) NENs and 16 with lung NENs] and compared SRS results with immunohistochemical (IHC) reactivity for sstr2, sstr3, sstr5 in sample tissues from primary (n = 54) and metastatic (n = 27) lesions and IHC reactivity for D2R in 23 samples from primary GI-NENs lesions.
Sstr2 was the commonest sstr expressed (65·4%) and was co-expressed with sstr3 and sstr5 in 32·1% and 24·7% of the specimens, respectively. In 67 of 81 specimens (82·7%), there was concordance of sstr2 immunohistochemistry with SRS findings (P < 0·001). D2R was expressed in only 8 of 23 (34·8%) GI-NENs while was co-expressed with sstr2 in all cases. SRS grade, as per Krenning scale, was higher in metastatic foci, large-size (>2 cm) tumours and GI-NENs, whereas sstr2 intensity was greater in GI compared to lung NENs. SRS grade showed higher correlation with sstr2 (r = 0·6, P < 0·001) and D2R (r = 0·5, P < 0·001) IHC intensity scores than tumour size (r = 0·4, P < 0·001) and sstr3 (r = 0·4, P < 0·001) intensity score.
Sstr2 IHC expression and SRS are useful tools for the diagnosis and management of NENs because they display a high concordance. IHC expression of DR2 seems to be of potential clinical significance in GI-NENs tumours.
神经内分泌肿瘤（NENs）中生长抑素（sstr1 - 5）和多巴胺（DR）受体的表达有助于通过生长抑素受体闪烁显像（SRS）进行肿瘤可视化诊断，并指导使用放射性标记的生长抑素类似物进行肽受体放射性核素治疗（PRRT）的特异性治疗。
研究NENs中sstrs、D2R的共表达与术前SRSs的关系。
前瞻性双中心研究。
我们分析了60例患者（44例胃肠道（GI）NENs和16例肺NENs）的术前SRS，并将SRS结果与原发性（n = 54）和转移性（n = 27）病变样本组织中sstr2、sstr3、sstr5的免疫组织化学（IHC）反应性以及23例原发性GI - NENs病变样本中D2R的IHC反应性进行比较。
sstr2是最常表达的sstr（65.4%），分别在32.1%和24.7%的标本中与sstr3和sstr5共表达。在81个标本中的67个（82.7%），sstr2免疫组织化学与SRS结果一致（P < 0.001）。D2R仅在23例GI - NENs中的8例（34.8%）中表达，而在所有病例中均与sstr2共表达。根据Krenning分级，SRS分级在转移灶、大尺寸（>2 cm）肿瘤和GI - NENs中更高，而sstr2强度在GI - NENs中比肺NENs更大。SRS分级与sstr2（r = 0.6，P < 0.001）和D2R（r = 0.5，P < 0.001）的IHC强度评分的相关性高于肿瘤大小（r = 0.4，P < 0.001）和sstr3（r = 0.4，P < 0.001）的强度评分。
sstr2 IHC表达和SRS是NENs诊断和管理的有用工具，因为它们显示出高度一致性。DR2的IHC表达在GI - NENs肿瘤中似乎具有潜在的临床意义。
